Hi. Good morning, everyone. I'm Ellie Merle, one of the biotech analysts here at Barclays. Thank you for joining us here in Sunny Miami. Very happy to have 4D Molecular Therapeutics here with us today ...

In this video, Jay Chhablani, MD, director of clinical research at the UPMC Vision Institute, professor of ophthalmology and vice chair of clinical trials at University of Pittsburgh School of ...

The MHRA has granted marketing authorisation for Eylea ® (aflibercept 8 mg) for the treatment of patients with macular oedema following retinal vein occlusion (RVO) including branch, central and ...

4D Molecular Therapeutics, Inc. ( FDMT) TD Cowen 46th Annual Health Care Conference March 3, 2026 10:30 AM EST ...

Add Yahoo as a preferred source to see more of our stories on Google. Feb 17 (Reuters) - Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients ...

Regeneron Pharmaceuticals REGN put up a decent performance for the fourth quarter of 2025 and full-year 2025 (reported last month) with overall revenues rising despite a continued decline in sales of ...

Treatment-naïve BRVO eyes showed logMAR BCVA improvement (0.64 to 0.41) alongside CRT reduction (527 µm to 285 µm) over short-term follow-up with SB15. Central RVO eyes improved from logMAR 1.29 to 0.

Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...

Axpaxli shows modest advantage over Eylea in trial Retinal specialists may value trial data more than investors, analyst says Ocular plans FDA discussions and marketing application The ...

The primary difference between the Wegovy pill and the injection is how you take them and how often. The Wegovy pill is a daily tablet you swallow, while the Wegovy injection is a once-weekly shot you ...